发明授权
US09505844B2 Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
有权
抗人CCR7抗体,杂交瘤,核酸,载体,细胞,药物组合物和抗体固定载体
- 专利标题: Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
- 专利标题(中): 抗人CCR7抗体,杂交瘤,核酸,载体,细胞,药物组合物和抗体固定载体
-
申请号: US14489898申请日: 2014-09-18
-
公开(公告)号: US09505844B2公开(公告)日: 2016-11-29
- 发明人: Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
- 申请人: Sekisui Chemical Co., Ltd. , NB HEALTH LABORATORY CO., LTD.
- 申请人地址: JP Osaka JP Hokkaido
- 专利权人: SEKISUI CHEMICAL CO., LTD.,NB HEALTH LABORATORY CO., LTD.
- 当前专利权人: SEKISUI CHEMICAL CO., LTD.,NB HEALTH LABORATORY CO., LTD.
- 当前专利权人地址: JP Osaka JP Hokkaido
- 代理机构: Wenderoth, Lind & Ponack, L.L.P.
- 优先权: JP2010-217096 20100928
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61K31/713 ; A61K39/00
摘要:
An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.
公开/授权文献
信息查询